A Translational Tool to Facilitate Use of Apolipoprotein B for Clinical Decision-Making

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)

(2022) Elisa Waldmann et al.   PLoS One

2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

(2021) Glen J. Pearson et al.   CANADIAN JOURNAL OF CARDIOLOGY

Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients

(2021) Camilla Ditlev Lindhardt Johannesen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis

(2021) Nicholas A. Marston et al.   JAMA Cardiology

A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia

(2020) Maureen Sampson et al.   JAMA Cardiology

The clinical utility of apoB versus LDL-C/non-HDL-C

(2020) Ciaran N. Kohli-Lynch et al.   CLINICA CHIMICA ACTA

The extended lipid panel assay: a clinically-deployed high-throughput nuclear magnetic resonance method for the simultaneous measurement of lipids and Apolipoprotein B

(2020) Erwin Garcia et al.   Lipids in Health and Disease

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM

(2018) Michel R. Langlois et al.   CLINICAL CHEMISTRY

Discordance between lipoprotein particle number and cholesterol content

(2018) Eric P. Cantey et al.   Current Opinion in Endocrinology Diabetes and Obesity

Lipoprotein Insulin Resistance Index: A Lipoprotein Particle–Derived Measure of Insulin Resistance

(2014) Irina Shalaurova et al.   Metabolic Syndrome and Related Disorders

Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile

(2013) Seth S. Martin et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

P4 medicine: how systems medicine will transform the healthcare sector and society

(2013) Mauricio Flores et al.   Personalized Medicine

Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study)

(2011) Jennifer G. Robinson et al.   Journal of Clinical Lipidology

ApoB versus non-HDL-C: What to do when they disagree

(2009) Allan Sniderman et al.   Current Atherosclerosis Reports

Translating the A1C Assay Into Estimated Average Glucose Values

(2008) D. M. Nathan et al.   DIABETES CARE

Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice

(2008) Allan D. Sniderman   Journal of Clinical Lipidology